Prognostic gene expression signature for high-grade serous ovarian cancerJoshua Millstein, Scott D. Brown, Timothy Budden et al.|Annals of Oncology|2020Cited by 173
Getting the MOST out of follow-up: a randomized controlled trial comparing 3 monthly nurse led follow-up via telehealth, including monitoring CA125 and patient reported outcomes using the MOST (Measure of Ovarian Symptoms and Treatment concerns) with routine clinic based or telehealth follow-up, after completion of first line chemotherapy in patients with epithelial ovarian cancerPaul A. Cohen, Michael Friedländer, Val Gebski et al.|International Journal of Gynecological Cancer|2021Cited by 12